Early treatment window for predicting breast cancer response to neoadjuvant chemotherapy in the HR+/HER2- subgroup using diffuse optical tomography

Mirella L. Altoe, Alessandro Marone, Hyun K. Kim, Mariella Tejada, Hanina Hibshoosh, Hua Guo, Katherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Kevin Kalinsky, Dawn L. Hershman, Andreas H. Hielscher

    Research output: Chapter in Book/Report/Conference proceedingConference contribution

    Abstract

    This work evaluates changes in features of 3D breast images generated by a so-called dynamic optical tomographic imaging system (DOTBIS) during neoadjuvant chemotherapy (NAC). Images from 23 breast cancer patients were analyzes and correlated with respect to treatment outcome and status of hormone receptors and human epidermal growth factor receptors. Our data shows that the ratio of the mean value of deoxy-hemoglobin (ctHHbN) at two weeks after the first treatment compared to baseline was statistically significantly lower in patients that achieve a pathologic complete response (pCR) (0.77 ± 0.22) as compared to patients with a non-pCR (1.14 ± 0.24, P <.005). These observations indicate that early changes in DOTBIS images can potentially be used to predict breast cancer response to NAC and may allow a better way to customize therapy to HR+/HER2- patients in order to optimize treatment.

    Original languageEnglish (US)
    Title of host publicationMultiscale Imaging and Spectroscopy III
    EditorsPaul J. Campagnola, Kristen C. Maitland, Darren M. Roblyer
    PublisherSPIE
    ISBN (Electronic)9781510647596
    DOIs
    StatePublished - 2022
    EventMultiscale Imaging and Spectroscopy III 2022 - Virtual, Online
    Duration: Feb 20 2022Feb 24 2022

    Publication series

    NameProgress in Biomedical Optics and Imaging - Proceedings of SPIE
    Volume11944
    ISSN (Print)1605-7422

    Conference

    ConferenceMultiscale Imaging and Spectroscopy III 2022
    CityVirtual, Online
    Period2/20/222/24/22

    Keywords

    • Difuse optical tomography
    • HR+/HER2-
    • breast cancer
    • deoxy-hemoglobin
    • molecular subtype
    • neoadjuvant chemotherapy
    • pCR

    ASJC Scopus subject areas

    • Electronic, Optical and Magnetic Materials
    • Atomic and Molecular Physics, and Optics
    • Biomaterials
    • Radiology Nuclear Medicine and imaging

    Fingerprint

    Dive into the research topics of 'Early treatment window for predicting breast cancer response to neoadjuvant chemotherapy in the HR+/HER2- subgroup using diffuse optical tomography'. Together they form a unique fingerprint.

    Cite this